Trial Profile
Open label study evaluating the use of combination therapy of ezetimibe and statins [HMG-CoA reductase inhibitors] in patients with dyslipidemia in Colombia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary) ; HMG-CoA reductase inhibitors
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Organon
- 24 Apr 2008 New trial record.